CD44+CD24−/low cells account for 11%–35% of breast cancer cells, suggesting that they are a small but essential subpopulation of stem cells responsible for maintaining tumour heterogeneity and treatment resistance.71 This evidence concerns the gene CD24 and neoplasm.